Biohit Oyj (BIOBV.HE)
Biohit Oyj operates in the Biotechnology industry of the Healthcare sector, headquartered in Helsinki, UU, FI. The stock last traded at $2.70, up 0.75% on the session, giving a market capitalisation of $41.0M. Its beta of 0.57 implies it has historically moved less than the broad market.
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.
Biohit Oyj is most often compared with the following Healthcare names: